Fospropofol
Fospropofol, commercially recognized by its trade name Lusedra, is an intravenous sedative-hypnotic agent that holds significant therapeutic value. Predominantly, it is endorsed for sedation in adult patients who are set to undergo diagnostic or therapeutic procedures, including endoscopy.
Origins and Derivatives
Fospropofol is a prominent member of a series of water-soluble derivatives and prodrugs stemming from the universally recognized intravenous anesthetic agent, propofol. Of all the derivations explored, fospropofol has been earmarked as the most propitious candidate for clinical advancement to date.
Clinical Applications
Fospropofol's suitability for clinical use is buoyed by several advantageous attributes:
- Painless administration: Patients experience reduced discomfort at the intravenous administration site.
- Diminished hyperlipidemia risk: Prolonged administration is less likely to result in hyperlipidemia.
- Decreased bacteremia potential: The likelihood of bacteremia occurrence is minimized.
Given the pharmacological profile of fospropofol, it is frequently co-administered with opioids, notably fentanyl, to optimize therapeutic outcomes.
Clinical Pharmacology
Mechanism of Action
Acting as a prodrug, fospropofol undergoes metabolism by alkaline phosphatases, resulting in the production of its active metabolite, propofol. This biochemical transformation ensures that, in theory, each millimole (mmol) of fospropofol sodium yields an equivalent mmol of propofol. It's pertinent to note that 1.86 mg of fospropofol sodium corresponds to the molar equivalent of 1 mg of propofol.
Pharmacokinetics
Initial studies detailing the pharmacokinetics of fospropofol were retracted by the principal investigators. Regrettably, as of 2011, renewed findings remain elusive.
Regulatory Status
In light of its pharmacological properties and potential for misuse, fospropofol has been designated as a Schedule IV controlled substance under the United States' Controlled Substances Act.
General anesthetics (N01A) | ||||
---|---|---|---|---|
|
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD